Management of Superficial Vein Thrombophlebitis in Pregnancy

Diagnostic Confirmation

The American Society of Hematology recommends obtaining compression ultrasound imaging to confirm the diagnosis, measure exact thrombus length, assess distance from the saphenofemoral junction, and exclude concurrent deep vein thrombosis (DVT), as approximately 25% of patients with superficial vein thrombosis have underlying DVT 3
Left-sided involvement is more common (85% of cases) due to compression of the left iliac vein by the right iliac artery and the gravid uterus 4

For superficial vein thrombophlebitis ≥5 cm in length or extending above the knee, the American Society of Hematology provides a conditional recommendation for initiating prophylactic-dose low-molecular-weight heparin (LMWH) and continuing throughout the remainder of pregnancy and for at least 6 weeks postpartum, with low certainty of evidence due to lack of pregnancy-specific data 1, 2, 4
For superficial vein thrombophlebitis within 3 cm of the saphenofemoral junction, escalate to therapeutic-dose LMWH and treat as DVT-equivalent for at least 3 months total duration (continuing throughout pregnancy and postpartum) 3, 4

Fondaparinux and rivaroxaban, which are first-line agents in non-pregnant patients, should be avoided during pregnancy due to placental transfer and lack of safety data 2, 3
Either once-daily or twice-daily LMWH dosing regimens are acceptable, as both have similar efficacy 1, 4

Prescribe graduated compression stockings to reduce symptoms and prevent progression 3
Recommend early ambulation rather than bed rest, as immobility increases the risk of progression to DVT 3

Routine monitoring of anti-factor Xa levels to guide LMWH dosing is not recommended unless there are specific concerns about therapeutic levels or extremes of body weight 1
Monitor for extension into the deep venous system, which necessitates immediate escalation to therapeutic-dose anticoagulation 3
Approximately 10% of patients with superficial vein thrombosis develop thromboembolic complications at 3-month follow-up despite anticoagulation 3

Plan for scheduled delivery with discontinuation of therapeutic-dose LMWH 24 hours before anticipated delivery 4
Anticoagulation can be restarted 8-12 hours after delivery if no significant bleeding is present 4
Continue anticoagulation for at least 6 weeks postpartum (minimum total duration of 3 months from diagnosis) 4, 5

Do not use fondaparinux or direct oral anticoagulants during pregnancy due to placental transfer and lack of safety data 2, 3, 4
Do not use vitamin K antagonists (warfarin) during pregnancy due to teratogenic effects and embryopathy risk 4, 5

Active cancer, recent surgery, history of prior VTE or superficial vein thrombosis, involvement of the greater saphenous vein, severe symptoms, and proximity to the deep venous system all increase the risk of progression to DVT/PE and favor anticoagulation use 3